Article

Retina may provide clues to the severity of multiple sclerosis

Author(s):

Researchers at the Medical University of Vienna are focusing on how the retina can be used as a prognostic marker. Analyses revealed that retinal layer thinning as a result of an MS relapse predicts the severity of future relapses and the likelihood of disability.

Assessing the severity of multiple sclerosis (MS) is key as physicians seek a course of treatment for patients diagnosed with this disease, but it can prove to be challenging with existing methods.

A study by a team at the Medical University of Vienna is highlighting how the retina can be used as a prognostic marker. Analyses revealed that retinal layer thinning as a result of an MS relapse predicts the severity of future relapses and, hence, the likelihood of disability. The results of the study have now been published in Neurology.1

A team of esearchers led by Gabriel Bsteh and Thomas Berger from the Department of Neurology at MedUni Vienna/University Hospital Vienna, working in collaboration with the Department of Ophthalmology and Optometrics at MedUni Vienna/University Hospital Vienna, studied 167 MS patients over a period of more than 3 years.

According to the university, the team hypothesized that retinal damage due to relapse reflects the extent of damage in the brain. As the scientific analyses confirmed, the loss of approximately 5 µm of retinal layer thickness after optic neuritis equates to a doubling of the risk of permanent disability after the next relapse. These predictions could be used as the basis for treatment decisions in future: the results of the study suggest that more aggressive treatment is indicated where there is significant retinal layer thinning than would be the case for a smaller degree of thinning. This is true even if the patient has no disability or only slight disability at the time of measurement.

Prognostic technique already available
The researchers used optical coherence tomography (OCT) to measure retinal layer thickness. OCT is an imaging technique that uses infrared light to produce high-resolution three-dimensional images of very thin layers of tissue in the micrometre range (1 micrometre=1 thousandth of a millimetre). It is already used as a tool for diagnosing eye diseases such as glaucoma, and for evaluating disease progression.

"The technique for predicting the course of MS is therefore already available to us," said Bsteh, first author of the study. "As we discovered in the course of our clinical trial, measurements should be taken at initial diagnosis, directly when optic neuritis occurs in relapsing MS, and 6 months thereafter."

The retina as a window to the brain
Multiple sclerosis is a chronic inflammatory autoimmune disease that leads to the loss of axons and neurons throughout the entire nervous system. Although this damage often goes unnoticed by patients at first, its extent determines the prognosis for the severity of the disease. Since predictions about the course of the disease are important in MS for selecting the appropriate treatment, medical research has long been searching for reliable prognostic tools.

"In retinal layer thickness, we have found a new biomarker that represents a window to the brain, as it were," Bsteh added, summarizing the essence of the study. If the results are confirmed in larger follow-up studies, the technique could also be applied in routine clinical practice.

Reference

Gabriel Bsteh, Nik Krajnc, Katharina Riedl, Patrick Altmann, Barbara Kornek, Fritz Leutmezer, Stefan Macher, Christoph Mitsch, Philip Pruckner, Paulus Rommer, Gudrun Zulehner, Berthold Pemp, Thomas Berger; Retinal layer thinning after optic neuritis as a predictor of future relapse remission in relapsing multiple sclerosis. Neurology, Published July 2022. doi: 10.1212/WNL.0000000000200970

Related Videos
Adam Wenick, MD, chairs EyeCon session: New treatments in geographic atrophy from detection to intervention
David Eichenbaum, MD, presents advances in AMD therapy, highlights different mechanisms with a common goal
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
© 2024 MJH Life Sciences

All rights reserved.